PA
BBNX

Parallel Advisors’s Beta Bionics BBNX Stock Holding History

Parallel Advisors’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.89K Buy
248
+209
+536% +$2.49K ﹤0.01% 3316
2026
Q1 		$391 Buy
+39
New +$577 ﹤0.01% 3709

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Parallel Advisors's BBNX Position: Q2 2026 in Review

Parallel Advisors increased its Beta Bionics (BBNX) stake by 536% in Q2 2026, buying an estimated $2.49K and bringing the position to 248 shares worth $3.89K. The position accounts for ﹤0.01% of the portfolio, ranked #3316.

Parallel Advisors first reported a position in BBNX in Q1 2026 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Parallel Advisors held 248 shares of Beta Bionics worth $3.89K as of Q2 2026.
  • Parallel Advisors bought 209 Beta Bionics shares in Q2 2026, an estimated $2.49K.
  • Beta Bionics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3316 holding.
  • Parallel Advisors first reported a position in Beta Bionics in Q1 2026 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.